HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia
Conditions: official terms
Leukemia - Leukemia, Myeloid - Leukemia, Myeloid, Acute
Conditions: Keywords
Acute Myeloid Leukemia, idarubicin, Microtransplantation
Study Type
Interventional
Study Phase
Phase 3
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: idarubicin Type: Drug
Name: microtransplantation Type: Biological
Overall Status
Recruiting
Summary
To compare the antitumor efficacy and toxicity of Idarubicin and cytarabine in combination with or not with infusions of granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells in patients with newly diagnosed high-risk acute myeloid leukemia (AML).
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 60 Years
Minimum Age: 7 Years
Gender: Both
Criteria: Inclusion Criteria:

1. Having signed informed consent

2. Diagnosis was based on the French-American-British (FAB) and WHO criteria.

3. Age ≥ 7 years old

4. Age < 60 years old

Exclusion Criteria:

1.Patients with a blast crisis of chronic myeloid leukemia or acute promyelocytic leukemia
Location
The Affiliated Hospital of the Chinese Academy of Military Medical Science
Beijing, Beijing, China
Status: Recruiting
Contact: huisheng ai, M.D. - 86-01-66947126 - huishengai@163.com
Start Date
August 2011
Completion Date
December 2013
Sponsors
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Source
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page